Bertilimumab is a fully human anti-eotaxin monoclonal antibody, initially developed for treating allergic disorders, currently in pre-clinical development for Allergic Rhinitis treatment. The DrugMonitor™ Anti-Bertilimumab Antibody (VS-1224-YC187) is an anti-drug antibody (ADA) against Bertilimumab. This drug-based antibody is raised in mice immunized with the Bertilimumab. The anti-Bertilimumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Bertilimumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-CCL11 Recombinant Antibody (Bertilimumab)Recombinant human monoclonal antibody expressed in CHO binding to human CCL11. Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function. It was to be used to treat severe allergic disorders.
Afuco™ Anti-CCL11 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-724)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human CCL11. It is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function. It was to be used to treat severe allergic disorders.
There are currently no Customer reviews or questions for VS-1224-YC187. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.